NEW YORK (TheStreet) -- Biotechnology and health care are some of the hottest areas for investment these days. But how should investors differentiate between the plethora of companies working their way through clinical trials with what could be the latest and greatest drug therapy? Or those companies that are benefitting from aging baby boomers -- not to mention wading through the changes brought on by the Affordable Care Act? The pharmaceuticals and biotech sectors are also getting a boost from consolidation in the market.